4 results about "Integral membrane protein" patented technology

The application discloses a urine biomarker for ovarian cancer detection and a screening method and application thereof. The urine biomarker is selected from at least one of the following (1)-(5): (1) heterogeneous nuclear ribonucleoprotein A3; (2) polymeric immunoglobulin receptor; (3) small integral membrane protein 24; (4) collagen type V alpha 2 chain; and (5) microtubule-associated protein 2. The urine polypeptide group biomarker of the application has high sensitivity and specificity when used for ovarian cancer detection, and the detection process is simple and non-invasive, which is favorable for improving the early diagnosis rate of ovarian cancer and improving the survival period of ovarian cancer patients.

The disclosure concerns a method of analysing a sample comprising an intact membrane protein, in a sample comprising non-synthetic biological membrane material. The method involves irradiating a gas phase proto membrane protein ion with infrared irradiation from a laser source.

To provide anti-claudin 18.2 multispecific antibodies and uses thereof.SOLUTION: The present disclosure relates generally to immunoglobulin-related compositions (e.g., multispecific antibodies or antigen-binding fragments thereof) capable of binding to a claudin 18.2 protein. The multispecific antibodies of the present technology are useful in methods for detecting and treating a claudin 18.2 related cancer in a subject in need thereof. Claudins are integral membrane proteins that form tight junctions.SELECTED DRAWING: None

This invention presents the CVOM-2 Gram-negative bacterial strain of Caulobacter crescentus, which has a point mutation in the ompA2 gene resulting in the substitution of arginine 351 for alanine, and a null mutation in the rsaA gene that produces outer membrane vesicles (EMVs) with greater efficiency, quantified as the amount of protein / ml of original culture. These EMVs produce a lower inflammatory response than similar preparations obtained from wild-type Escherichia coli cells or cells modified to reduce this response, or even than preparations obtained from a Caulobacter crescentus strain with a wild-type cell envelope.Genetic methods are also presented that allow the modification of these membrane-bound extracellular matrices (MBs), resulting in the presence of a heterologous protein or antigen in soluble form within the vesicle lumen or associated with the vesicle membrane as part of an integral membrane protein. The antigen may be exposed to the lumen or the vesicle surface, or anchored to the outer membrane via lipids. These MBs induce the generation of antibodies against a heterologous protein present within them. MBs also have an adjuvant effect, inducing antibody generation in response to antigen concentrations that would not otherwise elicit this response.